Note 8 – Commitments and Contingencies

Yeda Research and License Agreement

During the three months ended March 31, 2025 and 2024, the Company recorded research and development expenses of $14,500 related to its Research and License Agreement with Yeda (the “Agreement”). As of March 31, 2025 and December 31, 2024, the Company had $145,000 and $130,500, respectively, of accrued research and development expenses pursuant to the Agreement with Yeda.

MD Anderson Sponsored Research Agreements

The Company recognized $445,000 and $324,000 of research and development expenses during the three months ended March 31, 2025 and 2024, respectively, associated with services provided by The University of Texas M.D. Anderson Cancer Center (“MD Anderson”) under the two agreements with MD Anderson dated November 2018 and February 2019, respectively. During the three months ended March 31, 2025, the Company executed Amendment No. 6 to the Sponsored Research Agreement, extending the term of the agreement by three months from February 28, 2025 through May 27, 2025, for an additional payment of $327,000 due upon execution. As of March 31, 2025 and December 31, 2024, the Company had $209,427 and $0, respectively, of prepaid research and development expenses, $343,544 and $16,545 of accrued research and development expenses and $1,114,372 and $1,189,372 of accounts payable, respectively, pursuant to the agreements with MD Anderson on the condensed consolidated balance sheets.

Litigation

Loss contingencies considered remote are generally not disclosed, unless they involve guarantees, in which case the guarantees would be disclosed. There can be no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows. Aside from the matters discussed above, there are no other known contingencies through the date of this filing.